WA-KYMETA
10.3.2020 13:02:17 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com )—the communications company making mobile global—announced the commercial availability of its next generation flat panel electronically steered antenna platform, the Kymeta u8. The new u8 terminal paired with Kymeta’s hybrid satellite-cellular connectivity services transforms the purchase and consumption of mobile data with an all-inclusive hardware, connectivity and services monthly subscription starting at $999. The Kymeta u8 is the world’s only commercially available flat panel electronically steered antenna built specifically for mobility and designed for the needs of both military and commercial customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005297/en/
The Kymeta u8 antenna enables complete coverage of the Ku-band with highly reliable electronic beam steering and no moving parts. It is available as an antenna, as a terminal, or in flyaway configurations, and it can be paired with Kymeta’s new satellite and hybrid satellite-cellular connectivity solutions.
Powered by top satellite service and cellular operators throughout the world, Kymeta Connect makes buying hardware, connectivity, network services, and global support as simple and predictable as buying a mobile phone plan. A variety of satellite or satellite-cellular airtime packages are available and provided in partnership with Intelsat and Cubic Telecom, among others. Customers will now have access to easily deployable and dependable mobile connectivity in places where reliable and affordable connectivity has not been available. Kymeta is also working with LEO satellite operators on technology and service collaborations as described in press announcements released during Satellite 2020.
“With our new u8 terminal paired with Kymeta Broadband connectivity and support, we are making mobile global with a fully managed, optimized, and easy to use blended service,” said Walter Berger, President and Chief Operating Officer, Kymeta. “It is a complete solution with an elegant simplicity that will be very attractive to companies who need predictable OPEX pricing for their regional mobile connectivity services. We believe this is an industry tipping point for unlocking new access to the internet in all parts of the world.”
“We look forward to expanding our successful partnership with Kymeta as they add Intelsat’s FlexMove managed service to their communications-on-the-move (COTM) connectivity solutions offerings. Working together, Kymeta and Intelsat are helping people stay connected wherever they need to be, no matter how remote or challenging the location,” said Samer Halawi, Chief Commercial Officer, Intelsat.
Kymeta’s mobile connectivity services will be available in the US, Europe, the Middle East, Asia Pacific, sub-Saharan Africa, and Oceania with services extending to future geographies in the coming months. Initial deployments will include the military, first responders, buses, vehicle fleets, small maritime vessels, ferries, trucks and trains.
Show attendees can sign up for a meeting or live driving demonstration of the Kymeta u8 by emailing marketing@Kymetacorp.com . Additionally, the Kymeta u8 video is live and available to watch at www.kymetacorp.com .
About Kymeta
Kymeta is unlocking the potential of satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for mobile connectivity. The company’s flat-panel satellite antenna, the first of its kind, and Kymeta™ Connect connectivity services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom